DUBLIN, Feb. 8, 2023
/PRNewswire/ -- Mallinckrodt
plc (NYSE American: MNK), a global specialty pharmaceutical
company, today announced that it will report fourth quarter 2022
earnings results for the period ended December 30, 2022, on
Tuesday, February 28, 2023.
A conference call for investors will begin at 8:30
a.m. ET. The call can be accessed as follows:
- Live Call Participant Registration (including dial-in):
https://register.vevent.com/register/BI6e1a95af3f634687b3c55b1ae6b4ffd8
- Audio Only Webcast Link (live and replay):
https://edge.media-server.com/mmc/p/mfaw2pmz
- At the Mallinckrodt website:
https://ir.mallinckrodt.com/
ABOUT MALLINCKRODT
Mallinckrodt is a global business
consisting of multiple wholly owned subsidiaries that develop,
manufacture, market and distribute specialty pharmaceutical
products and therapies. The Company's Specialty Brands reportable
segment's areas of focus include autoimmune and rare diseases in
specialty areas like neurology, rheumatology, hepatology,
nephrology, pulmonology, ophthalmology and oncology; immunotherapy
and neonatal respiratory critical care therapies; analgesics;
cultured skin substitutes and gastrointestinal products. Its
Specialty Generics reportable segment includes specialty generic
drugs and active pharmaceutical ingredients. To learn more about
Mallinckrodt, visit
www.mallinckrodt.com.
Mallinckrodt uses its website as a
channel of distribution of important company information, such as
press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the Company in advance of or in
lieu of distributing a press release or a filing with the U.S.
Securities and Exchange Commission (SEC) disclosing the same
information. Therefore, investors should look to the Investor
Relations page of the website for important and time-critical
information. Visitors to the website can also register to receive
automatic e-mail and other notifications alerting them when new
information is made available on the Investor Relations page of the
website.
CONTACTS
Investor Relations
Daniel Speciale
Global Corporate Controller & Chief Investor Relations
Officer
314-654-3638
daniel.speciale@mnk.com
Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com
Media
Michael Freitag / Aaron Palash / Aura
Reinhard
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
Mallinckrodt, the "M" brand mark and
the Mallinckrodt Pharmaceuticals logo are trademarks of a
Mallinckrodt company. © 2023 02/23.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-to-report-earnings-results-for-fourth-quarter-2022-301741804.html
SOURCE Mallinckrodt plc